A month after announcing that Adrian Rawcliffe is to succeed the retiring James Noble as chief executive in September, Adaptimmune (Nasdaq:ADAP) has revealed further management changes.
John Lunger, previously senior vice president for manufacturing and supply chain, has been promoted to chief patient supply officer as the Anglo-American biopharma gears up for commercial delivery of products.
Meanwhile, Rafael Amado, president of R&D, will this month leave the company, which calls itself a leader in T-cell therapy to treat cancer, and the firm is seeking both a chief medical officer and a chief financial officer, the latter being Mr Rawcliffe’s former role.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze